FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/27/2022
Back to search
Official data from USPTO
BRIXELLE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
12/27/2022
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
12/01/2020
Registration date
08/23/2022
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/23/2022
Last transaction
08/23/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
KR
Examiner
LAM, HAI-LY HUYNH
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Bilix Co., Ltd.
Representatives
James R Menker Holley & Menker, PA
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical agents affecting sensory organs; pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for peripheral nervous system; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for the treatment of viral diseases; pharmaceuticals for the treatment of erectile dysfunction; vaccines; anti-inflammatory preparations; medicines for intestinal disorders; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; ophthalmic preparations; biological preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical agents for epidermis; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; enzymes for medical purposes; diagnostic preparations for medical or veterinary purposes; immunoassay reagents for medical use; medical reagents for testing genetic identity for medical purposes; pharmaceutical preparations for neurological disease; pharmaceutical preparations for inflammatory diseases; pharmaceutical preparations for ocular and intraocular surgery; pharmaceutical preparations for rare autoimmune diseases in the nature of autoimmune lymphoproliferative syndromelupusmultiple sclerosis; pharmaceutical products for the treatment of rare autoimmune diseases and disorders; pharmaceutical products for the prevention and treatment of rare genetic diseases affecting red blood cells; medicated ointments for treating dermatological conditions; antibiotic ointments; mentholated ointment for medical use; anti-inflammatory ointments; chemical reagents for purposes of medical diagnosis; diagnostic preparations for diagnosing inflammatory diseases; diagnostic radiopharmaceutical preparations; pharmaceutical and biological preparations for use in diagnosisfor use as ultrasound and X-ray contrast reagents; human vaccine preparations; pharmaceutical preparations acting on the central nervous system; preparations for the treatment of asthma; medicines for dental purposes; dermatological pharmaceutical products; pharmaceutical preparations for skin care; pharmaceutical preparations for treating skin disorders; antibiotics; anti-cancer preparations; tumor suppressing agents; pharmaceutical products for treating respiratory diseases
Publications
History of USPTO decisions and trademark events.
32 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/01/2022
FIMP
FINAL DISPOSITION PROCESSED
12/01/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/23/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/23/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
08/23/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
07/12/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/22/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
06/22/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/07/2022
PUBO
PUBLISHED FOR OPPOSITION
06/07/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/18/2022
ALIE
ASSIGNED TO LIE
05/02/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/29/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/28/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/27/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/27/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/29/2021
GNFR
FINAL REFUSAL E-MAILED
10/29/2021
CNFR
FINAL REFUSAL WRITTEN
10/29/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/30/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/30/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/30/2021
RFNT
REFUSAL PROCESSED BY IB
05/17/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/26/2021
RFRR
REFUSAL PROCESSED BY MPU
04/26/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/23/2021
CNRT
NON-FINAL ACTION WRITTEN
04/22/2021
DOCK
ASSIGNED TO EXAMINER
04/21/2021
MAFR
APPLICATION FILING RECEIPT MAILED
01/26/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/22/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/21/2021
Continuous trademark protection
Get notified about every new filing that threatens BRIXELLE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.